FDA Expands Access to Unapproved Peptides Under New Policy
Health law expert warns of risks as compounding pharmacies begin selling wellness peptides.
1New Policy Expands Access
Effective October 29, 2026, a new HHS policy allows specialized compounding pharmacies to produce and sell six specific peptides. These substances, including BPC-157 and TB-500, were previously restricted by the FDA in 2023 due to significant safety concerns. This shift marks a major departure from standard federal drug regulation protocols.
2The Role of Peptides
Peptides are short chains of amino acids serving as protein building blocks. While some synthetic versions like insulin are FDA-approved medicines, wellness peptides remain unstudied and unverified. Influencers frequently promote these substances for muscle growth and recovery, often referring to specific combinations like the Wolverine stack without clinical evidence.
3Kennedy's Strategic Influence
Health and Human Services Secretary Robert F. Kennedy Jr. championed this policy as part of the MAHA movement agenda. Kennedy appointed eight committee members with industry ties to advise the FDA, leading to an 8-6 vote favoring access. This occurred despite repeated warnings from FDA scientists regarding insufficient safety data.
4Enforcement Discretion Mechanism
The FDA is utilizing enforcement discretion to bypass standard approval requirements for these six peptides. This legal tool allows the agency to choose not to enforce regulations, effectively looking the other way. While sometimes used during drug shortages, this approach removes the requirement for rigorous safety and efficacy testing protocols.
5Historical Regulatory Risks
Enforcement discretion has historically led to severe public health consequences when oversight is absent. Past cases, such as inaccurate diagnostic tests and the Theranos fraud, demonstrate how lack of monitoring allows unverified products to proliferate. Critics argue that applying this policy to wellness peptides mirrors these dangerous, unchecked regulatory gaps.
6Compounding Pharmacy Limitations
Compounding pharmacies are not required to test ingredients sourced from outside suppliers for quality or purity. Unlike FDA-approved drugs, these compounded products lack federal oversight regarding production standards. Consumers may assume pharmacist involvement implies safety, but federal law does not mandate the same rigorous evaluation for these specific substances.
7Impact on Medical Research
The decision to bypass formal regulation may discourage long-term commercial research into these peptides. FDA law typically incentivizes companies to conduct clinical trials to prove efficacy and safety. By signaling a lack of interest in formal evaluation, the agency may inadvertently stall potential discoveries of legitimate medical applications for peptides.
8Consumer Safety Outlook
While the policy increases consumer access, it simultaneously removes the safety net provided by the FDA. There is currently no regulator verifying the efficacy or safety of these substances sold at compounding pharmacies. Consumers are advised to remain cautious, as the lack of oversight leaves them vulnerable to potentially ineffective products.